Abstract:With identical major and minor human leukocyte antigen, how did GVHD develop in patients undergoing syngeneic- or auto-HCT? Glazier et al. [4] initially demonstrated in animal transplant models that the phenomenon indistinguishable from classic acute GVHD could develop in CsA-treated and lethally irradiated rats after syngeneic or autologous BM reconstitution. These findings were later confirmed by other researchers and subsequent studies using preclinical models and human samples from CsA-induced auto GVHD. These highlight the following key points; (1) autoreactive CD8 + T cell clones that recognize MHC class II determinants in association with Class II-associated invariant chain peptide (CLIP) molecules are responsible for the development of auto-GVHD, (2) regulatory T cells (Tregs) act as a counterpart to these CD8 + T cells and prevents auto-GVHD, (3) thymus has an essential role in generating both autoreactive and immunoregulatory T cells, (4) CsA treatment (potentially other calcineurin inhibitors) hampers the central tolerance process, wherein potentially autoreactive T cells are eliminated in the thymus. What can be said about these findings in CsA-induced auto-GVHD animal models as they pertain to spontaneous auto-GVHD cases? While instructive, it must be admitted that the mechanisms and factors driving CsA-induced auto-GVHD and spontaneous auto-GVHD remain to be completely elucidated. While thymopoiesis and central tolerance may play a fundamental role in mouse models of CsA-induced auto-GVHD, thymopoiesis does not contribute considerably to T cell reconstitution until at least 6 months post-transplant in patients [5]. Onset of auto-GVHD predominantly occurs within 2–3 weeks of transplant where thymic-independent peripheral expansion of infused T cells is likely to play the major role in immune reconstitution [6]. The origin of autoreactive CD8 + T cells against self-MHC II antigen are thus more likely to arise from break of peripheral tolerance than central tolerance. Although self-reactive T cells are deleted in the thymus through negative selection and are expected to be absent in the periphery, some can nevertheless be found in the blood. In this situation, break of peripheral tolerance leads to the expansion of autoreactive CD8 + T cells driven by self-antigens and cytokines elaborated from injured tissues, as well as innate immune activation incurred by preparative conditioning procedure. Indeed, it is likely that impairment in function and delayed reconstitution of Tregs, influenced by pre-treatment chemotherapy and host susceptibility factors is at the heart of spontaneous auto-GVHD pathology. In the context of peripheral tolerance, programmed death (PD) 1 and programmed death-ligand 1 (PD-L1) pathway may also contribute to drive autoinflammation in auto-GVHD. PD-1 −/ − phenotype mice develop a lupus-like glomerulonephritis and destructive arthritis, accompanied by the activation of potentially autoreactive T cells in vivo [7]. Beyond its influence on the effector T cells, PD-1 ligation increases the generation of induced T regs from naïve CD4 + T cells and enhances their suppressive function, ultimately enabling the restraint of pathogenic T cells that have escaped into the periphery [8]. In a murine allogeneic transplant model [9], while both ileum and heart had a similar repertoire of infiltrating T cells, the ileum was only susceptible to T-cell-mediated tissue destruction, whereas the heart was not. PD-L1 expression was significantly elevated in heart tissue but almost absent in the ileum. These findings suggest that the PD1-PD-L1 pathway may involve organ-specific peripheral tolerance mechanisms and play a role in either facilitating or protecting against T-cell-mediated tissue damage responsible for GVHD. Currently, a series of publications report that prior PD-1 blockade possibly alters the post-HCT course by amplifying the graft-versus-tumor effect while increasing the risk of GVHD [10]. Although most clinical reports on this topic are derived from allo-HCT settings, taken together, it is tempting to speculate that the previous exposure to anti-PD-1 treatment in our second case may have contributed to their susceptibility to developing auto-GVHD. In addition, the relatively high occurrence of auto-GVHD in the peri-engraftment period raises the possibility of a connection with engraftment syndrome. Moreover, engraftment syndrome and auto-GVHD have similar clinical manifestations and exhibit indistinguishable skin biopsy pathological findings. As Cornell et al. have suggested [11], auto-GVHD may fall on a spectrum with engraftment syndrome as an autoinflammatory consequence of breakdown in self-tolerance after auto-HCT.

Atopic dermatitis-like GVHD: clinical review of 11 cases

Atopic Dermatitis–like Presentation of Graft-Versus-host Disease: A Novel Form of Chronic Cutaneous Graft-Versus-host Disease

A case report of chronic graft-versus-host disease manifested as both atopic dermatitis-like and hypertrophic lichen planus-like lesions

Increased regulatory T cells and eosinophils characterize atopic dermatitis–like graft-versus-host disease compared with lichen planus–like graft-versus-host disease

Clinical features of 24 cases of scleroderma-like cutaneous graft-versus-host disease

Atopic Dermatitis-like Graft-versus-host Disease and Lichen Planus-like Graft-versus-host Disease: Alterations in Skin Barrier Function and Related Molecules

Cutaneous Chronic Graft-Versus-Host Disease: Clinical Manifestations, Diagnosis, Management, and Supportive Care

GVHD like skin eruption post-autologous stem cell transplantation

Clinical characteristics of acute graft-versus-host disease among different donors of allogeneic hematopoietic stem cell transplantation.

Occurrence and Severity of DLI Associated Chronic Gvhd Influence the Clinical Outcomes in Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

[Effect of Graft-Versus-host Disease on Relapse and Survival in 100 Patients after Allogeneic Hematopoietic Stem Cell Transplantation].

Disease progression, treatments, hospitalization, and clinical outcomes in acute GVHD: a multicenter chart review

Diagnosis and treatment of acute graft-versus-host disease after liver transplantation: Report of six cases

Chronic graft-versus-host disease: Pathogenesis and clinical management

Acute graft-vs-host disease: pathobiology and management

Natural History, Risk Factors and Prognostic Impact of Graft-Versus-Host Disease Classified According to the National Institute of Health Criteria in Patients Receiving Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

Retrospective single center analysis of outcome, risk factors and therapy in steroid refractory graft-versus-host disease after allogeneic hematopoietic cell transplantation

Unusual expansion of CD3+CD56+ natural killer T-like cells in peripheral blood after anticytokine treatment for graft-versus-host disease: A case report

[Clinical Characteristics of Acute Graft-Versus-host Disease Confined Solely to Gastrointestinal Tract after Allogeneic Hematopoietic Stem Cell Transplantation].

IL-7 and IL-10 Serum Levels Are Potential Immune Biomarkers for Acute Graft-Versus-Host Disease Following Unrelated Hematopoietic Stem Cell Transplantation

Current Approaches for the Prevention and Treatment of Acute and Chronic GVHD